Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR
| العنوان: | Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR |
|---|---|
| المؤلفون: | David Waltz, Felix Ratjen, Gautham Marigowda, Margaret Rosenfeld, Carlos Milla, Fang Liu |
| المصدر: | American Journal of Respiratory and Critical Care Medicine. 195:912-920 |
| بيانات النشر: | American Thoracic Society, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Male, Pulmonary and Respiratory Medicine, Spirometry, medicine.medical_specialty, Cystic Fibrosis, Aminopyridines, Cystic Fibrosis Transmembrane Conductance Regulator, Quinolones, Aminophenols, Critical Care and Intensive Care Medicine, Cystic fibrosis, Ivacaftor, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Forced Expiratory Volume, Internal medicine, medicine, Humans, Benzodioxoles, 030212 general & internal medicine, Child, Intensive care medicine, Adverse effect, Sweat test, medicine.diagnostic_test, business.industry, Lumacaftor, medicine.disease, Rash, Treatment Outcome, 030228 respiratory system, chemistry, Tolerability, Drug Therapy, Combination, Female, medicine.symptom, business, medicine.drug |
| الوصف: | Combination lumacaftor/ivacaftor has been shown to improve lung function and other endpoints in patients aged 12 years and older with cystic fibrosis and homozygous for F508del-CFTR, but it has not been assessed in younger patients.In this open-label phase III trial, we evaluated the safety, tolerability, pharmacodynamics, and efficacy of lumacaftor/ivacaftor combination therapy in patients aged 6-11 years with cystic fibrosis who were homozygous for F508del-CFTR.Patients (N = 58) received 200 mg lumacaftor/250 mg ivacaftor orally every 12 hours for 24 weeks in addition to their existing cystic fibrosis medications.Lumacaftor/ivacaftor was well tolerated; the safety profile was generally similar to that observed in larger lumacaftor/ivacaftor trials with older patients. Four patients discontinued (two because of drug-related adverse events: elevated liver transaminases, n = 1; rash, n = 1). No safety concerns were associated with spirometry. No significant changes in percent predicted FEVLumacaftor/ivacaftor was well tolerated in this young population; no new safety concerns were identified. Improvements in lung clearance index, sweat chloride, nutritional status, and health-related quality of life were observed after 24 weeks of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT01897233). |
| تدمد: | 1535-4970 1073-449X 0189-7233 |
| DOI: | 10.1164/rccm.201608-1754oc |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9edeb7fe911c5173cf49285f3b4699 https://doi.org/10.1164/rccm.201608-1754oc |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3b9edeb7fe911c5173cf49285f3b4699 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....3b9edeb7fe911c5173cf49285f3b4699 833 3 unknown 832.595397949219 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3b9edeb7fe911c5173cf49285f3b4699&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9edeb7fe911c5173cf49285f3b4699# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22David+Waltz%22">David Waltz</searchLink><br /><searchLink fieldCode="AR" term="%22Felix+Ratjen%22">Felix Ratjen</searchLink><br /><searchLink fieldCode="AR" term="%22Gautham+Marigowda%22">Gautham Marigowda</searchLink><br /><searchLink fieldCode="AR" term="%22Margaret+Rosenfeld%22">Margaret Rosenfeld</searchLink><br /><searchLink fieldCode="AR" term="%22Carlos+Milla%22">Carlos Milla</searchLink><br /><searchLink fieldCode="AR" term="%22Fang+Liu%22">Fang Liu</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>American Journal of Respiratory and Critical Care Medicine</i>. 195:912-920 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => American Thoracic Society, 2017. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2017 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Pulmonary+and+Respiratory+Medicine%22">Pulmonary and Respiratory Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Spirometry%22">Spirometry</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Cystic+Fibrosis%22">Cystic Fibrosis</searchLink><br /><searchLink fieldCode="DE" term="%22Aminopyridines%22">Aminopyridines</searchLink><br /><searchLink fieldCode="DE" term="%22Cystic+Fibrosis+Transmembrane+Conductance+Regulator%22">Cystic Fibrosis Transmembrane Conductance Regulator</searchLink><br /><searchLink fieldCode="DE" term="%22Quinolones%22">Quinolones</searchLink><br /><searchLink fieldCode="DE" term="%22Aminophenols%22">Aminophenols</searchLink><br /><searchLink fieldCode="DE" term="%22Critical+Care+and+Intensive+Care+Medicine%22">Critical Care and Intensive Care Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Cystic+fibrosis%22">Cystic fibrosis</searchLink><br /><searchLink fieldCode="DE" term="%22Ivacaftor%22">Ivacaftor</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%2Echemical%5Fcompound%22">chemistry.chemical_compound</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Forced+Expiratory+Volume%22">Forced Expiratory Volume</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Benzodioxoles%22">Benzodioxoles</searchLink><br /><searchLink fieldCode="DE" term="%22030212+general+%26+internal+medicine%22">030212 general & internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Child%22">Child</searchLink><br /><searchLink fieldCode="DE" term="%22Intensive+care+medicine%22">Intensive care medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Adverse+effect%22">Adverse effect</searchLink><br /><searchLink fieldCode="DE" term="%22Sweat+test%22">Sweat test</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Ediagnostic%5Ftest%22">medicine.diagnostic_test</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Lumacaftor%22">Lumacaftor</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Rash%22">Rash</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+Outcome%22">Treatment Outcome</searchLink><br /><searchLink fieldCode="DE" term="%22030228+respiratory+system%22">030228 respiratory system</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%22">chemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Tolerability%22">Tolerability</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Therapy%2C+Combination%22">Drug Therapy, Combination</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Esymptom%22">medicine.symptom</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Combination lumacaftor/ivacaftor has been shown to improve lung function and other endpoints in patients aged 12 years and older with cystic fibrosis and homozygous for F508del-CFTR, but it has not been assessed in younger patients.In this open-label phase III trial, we evaluated the safety, tolerability, pharmacodynamics, and efficacy of lumacaftor/ivacaftor combination therapy in patients aged 6-11 years with cystic fibrosis who were homozygous for F508del-CFTR.Patients (N = 58) received 200 mg lumacaftor/250 mg ivacaftor orally every 12 hours for 24 weeks in addition to their existing cystic fibrosis medications.Lumacaftor/ivacaftor was well tolerated; the safety profile was generally similar to that observed in larger lumacaftor/ivacaftor trials with older patients. Four patients discontinued (two because of drug-related adverse events: elevated liver transaminases, n = 1; rash, n = 1). No safety concerns were associated with spirometry. No significant changes in percent predicted FEVLumacaftor/ivacaftor was well tolerated in this young population; no new safety concerns were identified. Improvements in lung clearance index, sweat chloride, nutritional status, and health-related quality of life were observed after 24 weeks of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT01897233). ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1535-4970<br />1073-449X<br />0189-7233 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1164/rccm.201608-1754oc ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9edeb7fe911c5173cf49285f3b4699" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9edeb7fe911c5173cf49285f3b4699</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1164/rccm.201608-1754oc" linkWindow="_blank">https://doi.org/10.1164/rccm.201608-1754oc</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....3b9edeb7fe911c5173cf49285f3b4699 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1164/rccm.201608-1754oc
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 9
[StartPage] => 912
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Male
[Type] => general
)
[1] => Array
(
[SubjectFull] => Pulmonary and Respiratory Medicine
[Type] => general
)
[2] => Array
(
[SubjectFull] => Spirometry
[Type] => general
)
[3] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[4] => Array
(
[SubjectFull] => Cystic Fibrosis
[Type] => general
)
[5] => Array
(
[SubjectFull] => Aminopyridines
[Type] => general
)
[6] => Array
(
[SubjectFull] => Cystic Fibrosis Transmembrane Conductance Regulator
[Type] => general
)
[7] => Array
(
[SubjectFull] => Quinolones
[Type] => general
)
[8] => Array
(
[SubjectFull] => Aminophenols
[Type] => general
)
[9] => Array
(
[SubjectFull] => Critical Care and Intensive Care Medicine
[Type] => general
)
[10] => Array
(
[SubjectFull] => Cystic fibrosis
[Type] => general
)
[11] => Array
(
[SubjectFull] => Ivacaftor
[Type] => general
)
[12] => Array
(
[SubjectFull] => 03 medical and health sciences
[Type] => general
)
[13] => Array
(
[SubjectFull] => chemistry.chemical_compound
[Type] => general
)
[14] => Array
(
[SubjectFull] => 0302 clinical medicine
[Type] => general
)
[15] => Array
(
[SubjectFull] => Forced Expiratory Volume
[Type] => general
)
[16] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[17] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[18] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[19] => Array
(
[SubjectFull] => Benzodioxoles
[Type] => general
)
[20] => Array
(
[SubjectFull] => 030212 general & internal medicine
[Type] => general
)
[21] => Array
(
[SubjectFull] => Child
[Type] => general
)
[22] => Array
(
[SubjectFull] => Intensive care medicine
[Type] => general
)
[23] => Array
(
[SubjectFull] => Adverse effect
[Type] => general
)
[24] => Array
(
[SubjectFull] => Sweat test
[Type] => general
)
[25] => Array
(
[SubjectFull] => medicine.diagnostic_test
[Type] => general
)
[26] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[27] => Array
(
[SubjectFull] => Lumacaftor
[Type] => general
)
[28] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[29] => Array
(
[SubjectFull] => Rash
[Type] => general
)
[30] => Array
(
[SubjectFull] => Treatment Outcome
[Type] => general
)
[31] => Array
(
[SubjectFull] => 030228 respiratory system
[Type] => general
)
[32] => Array
(
[SubjectFull] => chemistry
[Type] => general
)
[33] => Array
(
[SubjectFull] => Tolerability
[Type] => general
)
[34] => Array
(
[SubjectFull] => Drug Therapy, Combination
[Type] => general
)
[35] => Array
(
[SubjectFull] => Female
[Type] => general
)
[36] => Array
(
[SubjectFull] => medicine.symptom
[Type] => general
)
[37] => Array
(
[SubjectFull] => business
[Type] => general
)
[38] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => David Waltz
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Felix Ratjen
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gautham Marigowda
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Margaret Rosenfeld
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Carlos Milla
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fang Liu
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 04
[Type] => published
[Y] => 2017
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 15354970
)
[1] => Array
(
[Type] => issn-print
[Value] => 1073449X
)
[2] => Array
(
[Type] => issn-print
[Value] => 01897233
)
[3] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[4] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 195
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => American Journal of Respiratory and Critical Care Medicine
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |